Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genfit SA ( (GNFT) ) has shared an announcement.
On February 6, 2025, GENFIT announced its plans to initiate two new clinical trials in the first quarter and expects multiple data readouts by year-end within its ACLF pipeline. The company’s strategic development in ACLF is informed by 2024 insights, including AI-driven analysis and KOL input, aiming to streamline trial execution and enhance patient recruitment. GENFIT is poised for a pivotal year with anticipated advancements and a strengthened financial outlook, underscoring its commitment to addressing unmet medical needs in liver disease.
More about Genfit SA
GENFIT is a late-stage biopharmaceutical company focused on addressing rare and life-threatening liver diseases, with a robust R&D portfolio targeting Acute-on-Chronic Liver Failure (ACLF) and other serious conditions like cholangiocarcinoma and urea cycle disorder. The company has extensive expertise in liver disease research and development, having achieved milestones such as the accelerated approval of Iqirvo® for Primary Biliary Cholangitis. GENFIT also has a diagnostic franchise and is headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA. It is listed on the Nasdaq and Euronext markets.
YTD Price Performance: 4.18%
Average Trading Volume: 8,424
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $194.5M
For a thorough assessment of GNFT stock, go to TipRanks’ Stock Analysis page.
